Drive the future of chronic insomnia treatment.
Pear Therapeutics is proud to introduce Somryst, the only FDA-authorized prescription digital therapeutic (PDT) that delivers cognitive behavioral therapy for insomnia (CBT-I) to treat chronic insomnia by improving the insomnia symptoms of patients who are 22 years of age or older.
Somryst is the first FDA-authorized PDT that treats chronic insomnia by improving the insomnia symptoms of patients who are 22 years of age or older. Somryst uses an app to deliver CBT-I, which is recommended as first-line treatment for all adults with chronic insomnia.1 By delivering treatment digitally, Somryst makes CBT-I accessible for anyone, anywhere.
In clinical trials over the course of 9 weeks, the therapeutic equivalent of Somryst delivered2-4*:
A sustained decline in insomnia symptom severity for most patients
No drug-induced side effects or dependency risk
Improvements that lasted up to 12 months for most patients, with many of them no longer meeting the clinical threshold for chronic insomnia
*Somryst was tested under the name Sleep Healthy Using the Internet (SHUTi), an early version of Somryst with equivalent content. In clinical studies, Somryst demonstrated persistent results at 6- and 12-month follow-ups. Somryst users may not experience any or all of these benefits.5
What are PDTs?
PDTs are a new class of therapeutics that use digital tools and software to treat serious diseases, ranging from insomnia to addiction. They are clinically validated, and unlike pharmaceutical treatments, they don’t come with a risk of dependency or drug-induced side effects.
They differ from health and wellness apps and wearable devices in that they are validated and authorized by the FDA, prescribed by a physician, and backed by clinical data.
At Pear Therapeutics, we see PDTs as an opportunity to deliver the best care possible. We’re leading the way in the emerging field of digital health with 2 other PDTs already helping patients.
Stay up to date
All fields are required
References: 1. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; for the Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. 2. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. Lancet Psychiatry 2016; 3:(4)333-341. 3. Batterham PJ, Christensen H, Mackinnon A, et al. Trajectories of change and long-term outcomes in a randomized controlled trial of internet-based insomnia treatment to prevent depression. BJPsych Open. 2017;3(5):228-235. doi:10.1192/bjpo.bp.117.005231. 4. Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up: a randomized clinical trial. JAMA Psychiatry. 2017;74(1):68-75. 5. Somryst Clinician Direction for Use.